During the past decade, University of Alabama at Birmingham Women & Infant Center conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 1 clinical trials were completed, i.e. on average, 10% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Alabama at Birmingham Women & Infant Center" #1 sponsor was "Pfizer" with 3 trials, followed by "University of Alabama at Birmingham" with 3 trials sponsored, "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins" with 2 trials sponsored, "BioNTech SE" with 1 trials sponsored and "Li-Cor, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Alabama at Birmingham Women & Infant Center" #1 collaborator was "Genentech, Inc." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator, "PapiVax Biotech, Inc." with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "University of Alabama at Birmingham Women & Infant Center" are "COVID-19" (2 trials), "Respiratory Tract Infection" (2 trials), "Anesthesia" (1 trials), "Endometrial Cancer" (1 trials) and "HPV16 Associated Cervical Cancer" (1 trials). Many other conditions were trialed in "University of Alabama at Birmingham Women & Infant Center" in a lesser frequency.

Most popular intervention types in "University of Alabama at Birmingham Women & Infant Center" are "Drug" (8 trials), "Biological" (4 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Arixtra (fondaparinux sodium)" (1 trials), "Atezolizumab" (1 trials), "BNT162b2" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Alabama at Birmingham Women & Infant Center" are 10 trials for "Female" genders and 2 trials for "All" genders.

Currently, there are NaN active trials in "University of Alabama at Birmingham Women & Infant Center". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in University of Alabama at Birmingham Women & Infant Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Alabama at Birmingham Women & Infant Center, 5 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".